About Xintela

Xintela’s goal is to create significant medical advances in the fields of regenerative medicine and cancer, with particular focus on the treatment of cartilage damage and brain tumours.

About the company

Xintela AB is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours.

The key to Xintela’s operations is the company’s patented marker technology  XINMARK®.  Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells. Thus, Xintela can provide a unique way of ensuring the quality of stem cells to be used in repairing damaged cartilage. XINMARK® technology also makes it possible to detect certain tumour cells and target a treatment to those cells to slow the tumour growth.

top

History

Xintela was founded in 2009 by the company’s CEO Evy Lundgren-Åkerlund. The company’s operations are based on many years of research and development undertaken by Evy and her team at the University of Lund and in Cartela AB.

In 2013, Xintela initiated its research and development operations with a focus on developing stem cell products for the repair of damaged cartilage. In 2014, research and development work in the field of brain tumour treatment was initiated.

Xintela has a broad and strong patent portfolio, including over 50 approved patents in important markets such as Australia, Europe, USA, Canada and Japan.

CEO Evy Lundgren talking to a scientist
top

Management team and Board

Xintela’s management team and Board have extensive experience from the Life Sciences industry, covering research and development of medical products in both preclinical and clinical phases. Also, the Board has broad experience within the field of regenerative medicine and possesses a wealth of knowledge and competence in the fields of economics and law.

Mangement Team

Evy Lundgren-Åkerlund, born 1957
Chief Executive Officer since 2009
Doctor of Medical Science, senior lecturer

Experience: Xintela’s founder. Extensive experience in biomedical research and development. Has previously held senior positions in both academia and industry. Founded Cartela AB and was CEO and Head of Research from 2000-2007. Was Director of Operations/CEO of Ideon Bioincuba­tor/Lund Life Science Incubator from 2008-2012.
No current assignments.
Previous assignments:
Board member of Xintela AB.
No. of shares: 4,402,000

Not independent in relation to the Company and its management or by major shareholders.

Gunnar Telhammar, born 1961
Hired as a CFO to the Company since 2013
Master of Science in Business and Economics, Lund University

Experience: Has held several positions as CFO, both in Sweden and abroad, and has been operating through his own consulting firm BioFinans AB for over 15 years.
Current assignments: CEO of BioFinans AB, CFO of AcouSort AB (Publ) and ImmuneBiotech AB. Member of the board of Targinta AB (Publ).
Previous assignments: CFO of A1M Pharma AB.
No. of shares: 175,000

Not independent in relation to the Company and its management, but independent of major shareholders.

Gregory Batcheller, born 1957
Chairman of the Board since 2011
LL.M, J.D., B.Sc. (Econ.)

Experience: Extensive experience in pharmaceuticals, biotech and medtech.
Current assignments: Chairman of the Board of Saga Diagnostics AB, Monocl AB and Immune Biotech Medical Sweden AB. Partner of Business Research Life Sciences Ltd. CEO of Stanbridge Corporation BVBA. Advisor to Aquilion AB.
Previous assignments: CEO of Pulsetten AB, which divested DuoCort Pharma AB to ViroPharma Inc. in 2011, Board member of Dermafol AB, Maas Biolab LLC (US) and OBV Freehold Limited. Chairman of the Board of NeuroVive Pharmaceutical AB, A1M Pharma AB and AcuCort AB.
No. of shares: 688,300

Not independent in relation to the Company and its management, but independent of major shareholders.

Thomas Areschoug, born 1972
CBO since August 2020
Ph.D.

Experience: Has extensive experience from biomedical R&D and business development in life science, most recently in a leading role at Business Sweden.
No current assignments.
Previous assignments:
Invest in Skåne, Xintela, Business Sweden
No. of shares: 20,000

Not independent in relation to the Company and its management, but independent of major shareholders.

Peter Ekolind, born 1964
COO since August 2020
MBA

Experience: Has extensive experience of marketing, sales and leadership in several global pharmaceutical companies in various senior positions such as marketing- business area- and country manager. He has also been CEO of Getinge Sverige AB and Avidicare AB.
Current assignments: Chief Operating Officer (COO) of Xintela AB, board member and CEO of Pekoli AB, board member of Nordic Gamekeeper Holding AB.
Previous assignments: Board member of In vitro Plant-tech AB, Avidicare AB, Airsonett AB, Getinge Sverige AB, Swedish Medtech Service AB.
No. of shares: 200,000

Not independent in relation to the Company and its management, but independent of major shareholders.

The Board

Gregory Batcheller, born 1957
Chairman of the Board since 2011
LL.M, J.D., B.Sc. (Econ.)

Experience: Extensive experience in pharmaceuticals, biotech and medtech.
Current assignments: Chairman of the Board of Saga Diagnostics AB, Monocl AB and Immune Biotech Medical Sweden AB. Partner of Business Research Life Sciences Ltd. CEO of Stanbridge Corporation BVBA. Advisor to Aquilion AB.
Previous assignments: CEO of Pulsetten AB, which divested DuoCort Pharma AB to ViroPharma Inc. in 2011, Board member of Dermafol AB, Maas Biolab LLC (US) and OBV Freehold Limited. Chairman of the Board of NeuroVive Pharmaceutical AB, A1M Pharma AB and AcuCort AB.
No. of shares: 688,300

Not independent in relation to the Company and its management, but independent of major shareholders.

Sven Kili, born 1967
Board member since 2014
Medical Doctor, orthopaedic specialist

Experience: Extensive experience in cell therapy. Sven is a surgeon with orthopaedic specialist training with many years’ expe­rience of successful development and commercialisation of cell and gene therapy products from senior positions in the pharmaceutical industry, including Genzyme, Sanofi Biosurgery and GlaxoSmithKline. Sven was also responsible for medical and regulatory issues in cell therapy at Geistlich Pharma. He maintains his clinical expertise in the National Health Service (NHS) in the UK.
Current assignments: Sven is a Board member as well as Chief Medical Officer (CMO) and Chief Operating Officer (COO) of Xintela. Sven is also Chairman of the Board of Sven Kili Consulting Ltd, and Board member of CCRM and SCB and on the Scientific Advisory Board of LGC. Previous assignments: Vice-President and Head of Cell & Gene Therapy Development in GlaxoSmithKline.
No. of shares: 330,427

Not independent in relation to the Company and its management, but independent of major shareholders.

Karin Wingstrand, born 1957
Board member since 2014
Pharmacist

Experience: Advisor to the life sciences industry. Previously employed as Global head of AstraZeneca’s Clinical Development, and Global head of AstraZeneca’s Pharmaceutical and Ana­lytical Research and Development.
Current assignments: Board member of Mevia AB, T-bo­laget AB, Aqilion AB, Xbrane Biopharma AB, Histolab Products AB, Winkon holding AB and Integrum AB.
Previous assignments: Swecure AB and Adenovir Pharma AB.
No. of shares: 105,000

Independent in relation to both the Company and its management as well as to major shareholders.

Lars Hedbys, born 1957
BOARD MEMBER SINCE 2021
PH.D

Experience: Lars Hedbys has significant experience from leading positions and board roles inthe pharmaceutical, biotech and MedTech industries with several senior positionsin AstraZeneca.
Current assignments: He currently has several board assignments including memberof the boards of RhoVac, Cell Invent and Scandinavian ChemoTech.
Previous assignments: CEO of Idogen, and Pharmiva.
No. of shares: 0

Independent in relation to both the Company and its management as well as to major shareholders.

Maarten de Château, born 1963
BOARD MEMBER SINCE 2021
MD, PH.D

Experience: More than fifteen years of experience from roles in clinical drug development and business development at Sanofi, Sobi and Camurus. Prior to that, he worked for five years as a stock analyst.
Current assignments: Maarten de Château is CEO of Sixera Pharma and Buzzard Pharmaceuticals. He serves as chairman of the Board of Atrogi and is on the boards of OxThera, Amarna Therapeutics, Beactica and Cavis Technologies.
Previous assignments: Maarten was cofounder and CEO of Cormorant Pharmaceuticals acquired by Bristol-Myers Squibb in 2016. Prior to that, he held the position of Medical Director at Swedish Orphan Biovitrum.
No. of shares: 1 282 051

Not independent in relation to the Company and its management, but independent of major shareholders.

top

Scientific advisors

More information to follow
Read more about our technology
top

Collaborations

An important part of Xintela’s business strategy is to collaborate with leading research groups and other companies. Through these collaborations, Xintela can both create interest for the company’s technology and, at the same time, generate income through licencing. Xintela has already initiated several national and international collaborations with players in the fields of regenerative medicine and cancer.

top

Career

We are always interested in receiving spontaneous applications. If you believe you can contribute new competencies and energy to our dynamic team, send your CV to our COO, peter@xintela.se.

When you send us your CV, you also give your consent according to our GDPR policy. You can contact us at any time and request that we delete your personal information.

top

GDPR policy

Here you will find Xintela's GDPR policy.

Download GDPR-policy (pdf in Swedish)
till Toppen